Stanley Capital-Backed Portfolio Company DSS Acquires MyMeds&Me
Stanley Capital Partners LLP (SCP) announced the acquisition of MyMeds&Me Limited (MMM) by its portfolio company Drug Safety and Pharmacovigilance Services Solutions (DSS). DSS is a global provider of pharmacovigilance services under the brand Bioclinica. The financial terms of the transaction are not being disclosed.
The combined, digital-first organization will provide a pharmacovigilance solution focused on the current and future requirements of the life sciences industry.
Read more about the acquisiton here.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Twice-Yearly Lenacapavir Injections Significantly Reduce HIV Risk, PURPOSE 2 Trial Shows
November 13th 2024Full Phase III PURPOSE 2 trial results suggest that twice-yearly lenacapavir could revolutionize HIV prevention by offering a convenient and effective long-acting option for individuals at risk of infection.
